Equitable Trust Co. Has $925,000 Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Equitable Trust Co. lowered its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 34.8% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 11,900 shares of the medical device company’s stock after selling 6,343 shares during the period. Equitable Trust Co.’s holdings in DexCom were worth $925,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Versant Capital Management Inc bought a new position in DexCom during the fourth quarter worth about $25,000. Riverview Trust Co grew its holdings in DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after purchasing an additional 232 shares during the period. Heck Capital Advisors LLC bought a new position in DexCom during the fourth quarter worth about $38,000. RPg Family Wealth Advisory LLC bought a new position in DexCom during the third quarter worth about $57,000. Finally, Covestor Ltd grew its holdings in DexCom by 53.7% during the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after purchasing an additional 335 shares during the period. Institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on DXCM shares. Leerink Partners reduced their price target on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Wells Fargo & Company boosted their price objective on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Citigroup boosted their price objective on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Royal Bank of Canada reduced their price objective on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Finally, Canaccord Genuity Group boosted their price objective on DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, DexCom currently has an average rating of “Moderate Buy” and an average target price of $98.41.

DexCom Stock Up 0.2 %

Shares of DXCM opened at $88.27 on Tuesday. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a market cap of $34.48 billion, a P/E ratio of 52.86, a P/E/G ratio of 2.26 and a beta of 1.14. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The firm has a 50 day simple moving average of $81.76 and a two-hundred day simple moving average of $75.11.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 42,342 shares of company stock worth $3,628,069 over the last three months. Corporate insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.